Keith Lemon's LemonAid

Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Hims & Hers Health, Inc. (NYSE: HIMS)

Retrieved on: 
Thursday, July 13, 2023
SPAC, Insurance, Humboldt Hill, California, American Urological Association, Prescription, AOV, Markup, STAT, Dermatology, Acquisition, California Franchise Tax Board, Patient, RO, Risk, Erectile dysfunction, ED, NYSE, Face, Pharmacy, DOJ, Drug Enforcement Agency, Fareva, Snap, Costco, Target, EPA, DEA, Social stigma, Mental, FTC, Amazon Pharmacy, FDA, Mental health, State, Business Insider, Record, AMG, Medicine, Hims & Hers Health, Outline, Mercedes-AMG, ITC, Public key certificate, Walmart, Drug, Clinic, Ground substance, Woman, GNC, Apostrophe, CAC, Physician, OTC, Sildenafil, Cerebral, Health, Social polarization, HIPAA, Keith Lemon's LemonAid, Pharmaceutical industry, Walgreens, Hers, Tadalafil

Download or view the report by visiting www.SprucePointCap.com and follow us on Twitter @SprucePointCap for additional information and exclusive updates.

Key Points: 
  • Download or view the report by visiting www.SprucePointCap.com and follow us on Twitter @SprucePointCap for additional information and exclusive updates.
  • Hims & Hers is a health and wellness e-commerce company that came public in January 2021 through a SPAC merger.
  • In fact, we believe they are “figureheads” who can be replaced at the whim of Hims & Hers management.
  • As a reminder, our full report, along with its investment disclaimers, can be downloaded and viewed at www.SprucePointCap.com .

23andMe Reports FY2023 Third Quarter Financial Results

Retrieved on: 
Wednesday, February 8, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Genetics, Machine learning, Annual general meeting, Marketing, PGS, Research, Telehealth, Food, American Society of Human Genetics, Food and Drug Administration, Family, Tax, Society, ASH, Squamous cell carcinoma, Advertising, ATM, Marker beacon, Wilms' tumor, Webcast, Society for Immunotherapy of Cancer, Immunotherapy, Genome, Human genetics, CD200R1, Drug development, EBITDA, Ashkenazi Jews, SAN, National Human Genome Research Institute, Clinical trial, Keith Lemon's LemonAid, FDA, Agricultural Research Service, Consumer service, GSK, Asthma, Interim, Growth, ASHG, Johns Hopkins, SITC, NHGRI, Therapy, Simvastatin, Pharmaceutical industry, Central Europe, Adjustment

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year 2023 (FY2023), which ended December 31, 2022. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports, and in particular the only company the FDA has authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The Company has also created the world’s largest crowdsourced platform for genetic research, which it is using to pursue drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • These reports are developed by 23andMe scientists using data and insights gathered from thousands of customers who have consented to participate in our research.
  • “Our fiscal third quarter results reflect solid revenue growth in our consumer business, despite the macro-economic headwinds, and give us confidence to raise our full year financial guidance,” said Joe Selsavage, Interim Chief Financial and Accounting Officer of 23andMe.
  • 23andMe is raising its full year guidance following Q3 FY2023 results.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Wednesday, February 8, 2023 to discuss the financial results for Q3 FY2023 and report on business progress.

Telehealth Market Size Worth $787.4 Billion By 2028 | CAGR: 36.5%: Grand View Research, Inc.

Retrieved on: 
Monday, January 17, 2022
Cloud, CAGR, Economic security, Providers, COVID-19, Adoption, Growth, Telehealth, Economy, Software, Health care, Health, Insurance, Internet, United States Secretary of Labor, Coronavirus, Exercise, Cigna, Conditional sentence, USD, AIG, Siemens Healthineers, Revenue, Awareness, Video game, Health insurance, Retail, Pharmaceutical industry, Keith Lemon's LemonAid, Patient

The global telehealth market size is expectedto reach USD 787.4 billion by 2028, registering a CAGR of 36.5% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • The global telehealth market size is expectedto reach USD 787.4 billion by 2028, registering a CAGR of 36.5% over the forecast period, according to a new report by Grand View Research, Inc.
  • The ongoing pandemic exposed the shortcomings of the existing healthcare systems and burdened global healthcare facilities & resources, thereby driving the demand for telehealth solutions.
  • The web-based delivery mode segment dominated the global market in the past owing to the high usage recorded among patients and healthcare providers.
  • Grand View Research has segmented the global telehealth market based on product type, delivery mode, end-use, and region:
    Telehealth Product Type Outlook (Revenue, USD Million, 2016 - 2028)

Telehealth Market Size Worth $787.4 Billion By 2028 | CAGR: 36.5%: Grand View Research, Inc.

Retrieved on: 
Monday, January 17, 2022
Cloud, CAGR, Economic security, Providers, COVID-19, Adoption, Growth, Telehealth, Economy, Software, Health care, Health, Insurance, Internet, United States Secretary of Labor, Coronavirus, Exercise, Cigna, Conditional sentence, USD, AIG, Siemens Healthineers, Revenue, Awareness, Video game, Health insurance, Retail, Pharmaceutical industry, Keith Lemon's LemonAid, Patient

The global telehealth market size is expectedto reach USD 787.4 billion by 2028, registering a CAGR of 36.5% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • The global telehealth market size is expectedto reach USD 787.4 billion by 2028, registering a CAGR of 36.5% over the forecast period, according to a new report by Grand View Research, Inc.
  • The ongoing pandemic exposed the shortcomings of the existing healthcare systems and burdened global healthcare facilities & resources, thereby driving the demand for telehealth solutions.
  • The web-based delivery mode segment dominated the global market in the past owing to the high usage recorded among patients and healthcare providers.
  • Grand View Research has segmented the global telehealth market based on product type, delivery mode, end-use, and region:
    Telehealth Product Type Outlook (Revenue, USD Million, 2016 - 2028)

23andMe Agrees to Acquire Lemonaid Health

Retrieved on: 
Friday, October 22, 2021
23andMe, Research, Efficiency, Entrepreneurship, Genome, Failure, CA, Â, Eastern Time Zone, Keith Lemon's LemonAid, Algorithm, Common stock, Transaction, Patient, Genetics, General manager, Degenerative disease, Food, Health care, Telehealth, Lijun International Pharmaceutical (Holding) Co. Ltd., Prescription, Communication, Company, CEO, Morgan, Lewis & Bockius, Health, Food and Drug Administration, Acquisition, Publication, Protocol, Therapy, GLOBE, Pharmacy, Philosophy, Pharmaceutical industry

23andMe to host investor webcast today at 10:00 AM ET   SUNNYVALE, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the signing of a definitive merger agreement with Lemonaid Health, Inc., an on-demand platform for accessing medical care and pharmacy services online. Under the merger agreement, the purchase price is $400 million (subject to certain customary downward adjustments), of which 25% will be paid in cash and 75% in shares of 23andMe Class A Common Stock. The acquisition is expected to close by the end of 2021.

Key Points: 
  • Paul Johnson, CEO and Co-Founder of Lemonaid Health, will become the General Manager of the 23andMe consumer business, and in that role, will continue to run the Lemonaid Health services.
  • Lemonaid Healths focus on the patient and its philosophy of delivering individualized care fits perfectly with our mission of empowering people to take control of their health.
  • Lemonaid Health offers patients affordable and direct online access to medical care, from consultation through treatment, for a number of common conditions.
  • 23andMes mission-driven focus on empowering and transforming the healthcare experience is perfectly aligned with Lemonaid Healths founding principle to improve access to quality healthcare, said Paul Johnson, CEO and Co-Founder of Lemonaid Health.

Lemonaid Health Expands Internationally with U.K. Launch in Partnership with Drugstore Chain Boots

Retrieved on: 
Tuesday, August 3, 2021
Companies, Walgreens Boots Alliance, Walgreens, Boots

LONDON and SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- Lemonaid Health , a San Francisco-based online healthcare company, is expanding internationally with the launch of its services in the United Kingdom in partnership with Boots UK .

Key Points: 
  • LONDON and SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- Lemonaid Health , a San Francisco-based online healthcare company, is expanding internationally with the launch of its services in the United Kingdom in partnership with Boots UK .
  • Boots is the U.K.'s leading pharmacy-led health and beauty retailer and is part of the WBA (Walgreens Boots Alliance) group.
  • Lemonaid Health medical professionals have helped hundreds of thousands of patients get access to convenient, high-quality healthcare since its founding more than seven years ago.
  • "The partnership with Boots UK will enable us to expand our services internationally and help more patients access convenient affordable private healthcare in the coming years."

Lemonaid Health Expands Internationally with U.K. Launch in Partnership with Drugstore Chain Boots

Retrieved on: 
Tuesday, August 3, 2021
Companies, Walgreens Boots Alliance, Walgreens, Boots

LONDON and SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- Lemonaid Health , a San Francisco-based online healthcare company, is expanding internationally with the launch of its services in the United Kingdom in partnership with Boots UK .

Key Points: 
  • LONDON and SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- Lemonaid Health , a San Francisco-based online healthcare company, is expanding internationally with the launch of its services in the United Kingdom in partnership with Boots UK .
  • Boots is the U.K.'s leading pharmacy-led health and beauty retailer and is part of the WBA (Walgreens Boots Alliance) group.
  • Lemonaid Health medical professionals have helped hundreds of thousands of patients get access to convenient, high-quality healthcare since its founding more than seven years ago.
  • "The partnership with Boots UK will enable us to expand our services internationally and help more patients access convenient affordable private healthcare in the coming years."